SYSADOA(Symptomatic slow-acting drugs in osteoarthritis, JOINS®) : The role of osteoarthritis treatment
SYSADOA(Symptomatic slow-acting drugs in osteoarthritis, JOINS®) : 골관절염 치료를 위한 역할
The Global Burden of Disease Study highlighted a 113.3% increase in osteoarthritis (OA) cases globally, with Korea showing notably high prevalence rates, especially for knee OA. Herbal symptomatic slowacting drugs in OA (SYSADOA), such as JOINS® which contains extracts from Clematis mandshurica, Trichosanthes kirilowii, and Prunella vulgaris, have emerged as effective treatments. JOINS® has demonstrated significant anti-inflammatory and cartilage-protective effects through inhibiting key inflammatory cytokines and enzymes involved in cartilage degradation. Clinical trials comparing JOINS® to conventional NSAIDs and SYSADOAs revealed similar efficacy in pain management and functional improvement with lower incidences of gastrointestinal issues and no significant cardiovascular risks, positioning it as a viable long-term treatment option for OA. This evidence supports the potential of herbal SYSADOAs, particularly JOINS®, as safe and effective alternatives for OA management, emphasizing the need for comprehensive treatment strategies in the face of rising OA prevalence.
Sung Hoon Chung [ 정성훈 | Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. ]
Young Hyun Koo [ 구영현 | Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. ]
Eun Joo Choi [ 최은주 | Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea./Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, South Korea. ]
Corresponding Author